MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4

Area of Science:

• Biochemistry
• Oncology
• Cell Biology

Background:

• Monocarboxylate transporter 1 (MCT1) is a key protein in cancer metabolism.
• MCT1 inhibition is a potential anti-cancer strategy targeting lactate transport and glycolysis.
• The precise mechanism of MCT1 inhibition in cancer is not fully understood.

Purpose of the Study:

• To investigate the effect of MCT1 inhibition on cancer cell proliferation and metabolism.
• To determine whether MCT1 inhibition disrupts lactate or pyruvate transport in cancer cells.
• To explore the therapeutic potential of MCT1 inhibitors in breast cancer models.

Main Methods:

• Utilized breast cancer cell lines co-expressing MCT1 and MCT4.
• Administered acute MCT1 inhibition.
• Assessed pyruvate and lactate transport.
• Measured glycolytic flux.
• Evaluated cell proliferation in vitro and tumor growth in vivo using mammary fat pad xenografts.

Main Results:

• MCT1 inhibition impaired proliferation of glycolytic breast cancer cells.
• Inhibition disrupted pyruvate export, but not consistently lactate transport or glycolytic flux.
• High MCT1 expression correlated with poor prognosis in breast and lung cancer patients.
• MCT1 loss-of-function reduced breast cancer cell proliferation and xenograft tumor growth.

Conclusions:

• MCT1 inhibition primarily affects cancer cell proliferation by disrupting pyruvate export, rather than lactate transport or glycolysis.
• Elevated MCT1 expression in glycolytic cancers promotes pyruvate export, and its inhibition enhances oxidative metabolism and reduces proliferation.
• These findings provide a novel mechanistic insight into MCT1 inhibitor action and support their development as anti-cancer therapeutics.